Epigenomics' Epi proColon Blood Test Finally Makes The Grade With FDA

This article was originally published in The Gray Sheet

13 Apr 2016
News

Executive Summary

FDA approved the first blood-based colorectal cancer screening test, developed by Epigenomics, after a challenging regulatory path for the product, including a 2014 not-approvable letter.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Industries
Medical Device
Subjects
Regulation
Approvals

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Medical Device Regulation Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT034691

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT034691

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Epigenomics' Epi proColon Blood Test Finally Makes The Grade With FDA

News

Executive Summary

Related Content

Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert